臨床外科78巻12号

2023年11月発行

特集 胃癌に対するconversion surgery—Stage Ⅳでも治したい！

各論

腹膜播種を有する胃癌に対するconversion surgery

著者： 齋藤心¹ 山口博紀² 金丸理人¹ 大澤英之² 高橋和也¹ 金子勇貴¹ 倉科憲太郎¹ 細谷好則¹ 佐田尚宏¹ 北山丈二¹

所属機関： ¹自治医科大学消化器一般外科 ²自治医科大学臨床腫瘍科

ページ範囲：P.1349 - P.1355

文献概要

【ポイント】
◆腹膜播種陽性胃癌に対するIp-PTX＋SOX療法は，安全で有効な治療である．
◆腹膜播種奏効例に対するconversion surgeryは，予後改善に貢献できる可能性がある．
◆高度腹水を伴う胃癌腹膜播種症例でも，CART併用Ip-PTX＋SOX療法により腹水コントロールが期待できる．

参考文献

1）Sung H, Ferlay J, Siegel RL, et al：Global Cancer Statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71：209-249, 2021

2）Karimi P, Islami F, Anandasabapathy S, et al：Gastric cancer：descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 23：700-713, 2014

3）Yoo CH, Noh SH, Shin DW, et al：Recurrence following curative resection for gastric carcinoma. Br J Surg 87：236-242, 2000

4）Kitayama J, Saito S, Yamaguchi H, et al：ASO author reflections：repeated intraperitoneal paclitaxel with systemic chemotherapy as the first-line treatment for peritoneal malignancy. Ann Surg Oncol 28：3871-3872, 2021

5）Saito S, Yamaguchi H, Ohzawa H, et al：Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases. Ann Surg Oncol 28：3863-3870, 2021

6）Armstrong DK, Bundy B, Wenzel L, et al：Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354：34-43, 2006

7）Soma D, Kitayama J, Konno T, et al：Intraperitoneal administration of paclitaxel solubilized with poly（2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate）for peritoneal dissemination of gastric cancer. Cancer Sci 100：1979-1985, 2009

8）Kinoshita J, Yamaguchi T, Moriyama H, et al：Current status of conversion surgery for stage Ⅳ gastric cancer. Surg Today 51：1736-1754, 2021

9）Ishigami H, Fujiwara Y, Fukushima R, et al：Phase Ⅲ trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis：PHOENIX-GC trial. J Clin Oncol 36：1922-1929, 2018

10）Ye Z, Yu P, Cao Y, et al：Prediction of peritoneal cancer index and prognosis in peritoneal metastasis of gastric cancer using NLR-PLR-DDI score：a retrospective study. Cancer Manag Res 14：177-187, 2022

11）Kitayama J, Ishigami H, Yamaguchi H, et al：Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg 2：116-123, 2018

12）Koizumi W, Narahara H, Hara T, et al：S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer（SPIRITS trial）：a phase Ⅲ trial. Lancet Oncol 9：215-221, 2008

13）Janjigian YY, Shitara K, Moehler M, et al：First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma（CheckMate 649）：a randomised, open-label, phase 3 trial. Lancet 398：27-40, 2021

14）Kang YK, Chen LT, Ryu MH, et al：Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer（ATTRACTION-4）：a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23：234-247, 2022

15）Ishigami H, Kitayama J, Kaisaki S, et al：Phase Ⅱ study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 21：67-70, 2010

16）Eiseman JL, Eddington ND, Leslie J, et al：Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34：465-471, 1994

17）Ohzawa H, Kimura Y, Saito A, et al：Ratios of miRNAs in peritoneal exosomes are useful biomarkers to predict tumor response to intraperitoneal chemotherapy in patients with peritoneal metastases from gastric cancer. Ann Surg Oncol 27：5057-5064, 2020

18）Wei M, Yang T, Chen X, et al：Malignant ascites-derived exosomes promote proliferation and induce carcinoma-associated fibroblasts transition in peritoneal mesothelial cells. Oncotarget 8：42262-42271, 2017

19）Yoshida K, Yamaguchi K, Okumura N, et al：Is conversion therapy possible in stage Ⅳ gastric cancer：the proposal of new biological categories of classification. Gastric Cancer 19：329-338, 2016